Carl Wilson Harris, Iii

Title: Innovations by Carl Wilson Harris, III

Introduction

Carl Wilson Harris, III is an accomplished inventor based in South San Francisco, CA. He has made significant contributions to the field of medical technology, particularly in the treatment of aggressive non-Hodgkin lymphoma. His innovative approach aims to improve patient outcomes and reduce the adverse effects associated with conventional treatments.

Latest Patents

Harris holds a patent titled "Predicting Tolerability in Aggressive Non-Hodgkin Lymphoma." This patent describes systems and methods that enhance the ability to predict which patients with lymphoma can tolerate specific treatments. By utilizing a machine-learning model, the method generates a score that indicates the degree of tolerance a patient may have towards a particular treatment. This advancement allows for more personalized treatment plans, potentially sparing patients from harsh therapies that may not be suitable for them. He has 1 patent to his name.

Career Highlights

Harris is currently employed at Genentech, Inc., a leading biotechnology company known for its innovative approaches to medicine. His work focuses on developing systems that leverage data to improve treatment outcomes for patients suffering from lymphoma. His dedication to advancing medical technology has positioned him as a key player in his field.

Collaborations

Harris collaborates with talented professionals, including Tina Geritz Nielsen and Joseph Nathaniel Paulson. These partnerships enhance the research and development efforts at Genentech, fostering an environment of innovation and excellence.

Conclusion

Carl Wilson Harris, III exemplifies the spirit of innovation in the medical field through his groundbreaking work on predicting treatment tolerability in lymphoma patients. His contributions not only advance medical technology but also significantly impact patient care and treatment strategies.